<DOC>
	<DOCNO>NCT01489618</DOCNO>
	<brief_summary>The main objective study evaluate compare specific antibody response `` prime-boost `` vaccine strategy combine seven valence pneumococcal conjugate vaccine ( PnCj ) prime W0 follow administration pneumococcal capsular polysaccharide vaccine ( PPS ) boost W4 , administration pneumococcal capsular polysaccharide vaccine ( PPS ) alone W4 patient common variable immunodeficiency .</brief_summary>
	<brief_title>`` Prime Boost '' Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine ( s0 ) Polysaccharide Anti- Pneumococcal Vaccine ( s4 ) Compared Polysaccharide Anti- Pneumococcal Vaccine Alone ( s4 ) In Patients With Common Variable Immunodeficiency</brief_title>
	<detailed_description>Main objective : The main objective study evaluate compare specific antibody response `` prime-boost `` vaccine strategy combine seven valence pneumococcal conjugate vaccine ( PnCj ) prime W0 follow administration pneumococcal capsular polysaccharide vaccine ( PPS ) boost W4 , administration pneumococcal capsular polysaccharide vaccine ( PPS ) alone W4 patient common variable immunodeficiency . Secondary objective : - Evaluation comparison specific antibody response seven pneumococcal serotypes , share PnCj PPS vaccine ( 4 , 6B , 9V , 14 , 18C , 19F , 23F ) , two serotypes PPS vaccine ( 1 , 5 ) 4 week single ( W8 patient Group 1 ) first vaccination ( W4 patient group 2 ) . - Evaluation duration specific antibody response week 24 - Evaluation T CD4 lymphocyte response ( proliferation cytokine production ) CRM protein - Study Immunoglobulin V gene repertoire ( immunoscope ) vaccination . - Safety vaccine - Effect vaccine strategy frequency Streptococcus pneumoniae infection ( bronchitis , sinusitis recurrent upper respiratory tract ) EXPERIMENTAL METHODS Study design Randomised , multicentric , control phase II study immunological efficacy `` prime boost '' strategy combine sequential administration PnjC PPS anti-pneumococcal vaccine , compare administration PPS vaccine alone , patient common variable immunodeficiency . After randomisation ( W-4 ) 72 patient assign two follow group : - Group 1 : patient single administration PPS ( one dose W4 ) . 25 patient randomise group . - Group 2 : patient receive first boost PnCj ( one dose W0 ) one administration PPS vaccine ( one dose W4 ) . 47 patient randomise group . R : 1 :2 ( Group1 :2 ) The final evaluation study week 12 ; i.e 4 week administration PPS vaccine two group patient . A follow patient week 48 propose patient order evaluate duration antibody response wek 48 . DURATION OF THE STUDY - Inclusion period : 18 month - vaccination period : 2 month - Patients follow-up : 7 month Number patient : 72 PRIMARY AND SECONDARY EFFICACY ENDPOINTS The pneumococcal conjugate vaccine ( PnCj ) vaccin contain follow 7 pneumococcal serotypes : 4 , 6B , 9V , 14 , 18C , 19F , 23F . The pneumococcal capsular polysaccharide vaccine ( PPS ) contain 23 pneumococcal serotypes share seven serotypes include PnCJ . Primary endpoint : The primary end point study proportion responder serotype contain PnjC vaccine two group study accord 4 category : 5-7 ; 3-4 ; 2-1 0 . A responder define rise ( least two fold baseline ) antibody titer specific pneumococcal serotypes . Secondary endpoint : - The following parameter evaluate compare two group study : La réponse immunitaire anticorps vis-à-vis de différents sérotypes vaccinaux communs - geometric mean specific antibody titer - proportion patient experience increase specific antibody level &gt; 1 µg/ml - Evaluation prim effect PnCj vaccine group 2 - Duration specific antibody reponses week 24 - CD4 T lymphocyte response CRM protein ( proliferative cytokine production ) two group study week 0 , 8 12 . - Safety vaccine - Effect vaccine stategies frequency Streptococcus pneumoniae infection ( bronchitis , sinusitis recurrent upper respiratory tract ) STATISTICAL CONSIDERATIONS The initial hypothesis study superiority prim strategy . Expected response : 0 % group 1 ( PPS alone ) 30 % group 2 ( PnCj vace PPS ) . The number patient base power 84 % . The primary end point proportion responder serotype contain PnCj vaccine 2 group . The percentage patient group compare Fisher 's exact test . Mann-Whitney test Wilcoxon pair test use comparison antibody level percentage respond patient respectively .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Age &gt; 18 year &lt; 65 year Common variable immunodeficiency accord WHO criterion , Patients treat intravenous subcutaneous immunoglobulin . Written inform consent Absence acute infection , evolutive disease relate ( cancer , autoimmune disease… ) IgG subclass deficiency IgA selective deficiency , Other primary humoral deficiency ( Xlinked agammaglobulinemia , Hyper IgM syndrome ) , Long course treatment corticosteroid &gt; 5mg per day Chemotherapy last 3 year , Prior pneumococcal vaccination last 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Common variable immunodeficiency</keyword>
	<keyword>pneumococcal vaccine</keyword>
	<keyword>prime boost</keyword>
</DOC>